Chimerix, Inc. (CMRX)

NASDAQ: CMRX · IEX Real-Time Price · USD
0.22 (12.43%)
At close: May 27, 2022 4:00 PM
-0.03 (-1.51%)
After-hours:May 27, 2022 7:59 PM EDT

Company Description

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases.

The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy.

The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications.

Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Chimerix, Inc.
Chimerix Logo
CountryUnited States
IPO DateApr 11, 2013
SectorHealth Care
CEOMichael Sherman

Contact Details

2505 Meridian Pkwy Ste 100
Durham, North Carolina 27713-2288
United States
Phone919 806 1074

Stock Details

Ticker SymbolCMRX
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001117480

Key Executives

Michael A. Sherman M.B.A.Chief Executive Officer, President and Director
Michael T. Andriole M.B.A.Chief Business Officer, Secretary and Chief Financial Officer
Dr. Allen S. Melemed M.B.A., M.D.Chief Medical Officer
David Jakeman CPAExecutive Director of Finance and Accounting and Principal Accounting Officer
Dr. Roy W. WareChief Manufacturing and Technology Officer
Dr. Randall LanierChief Science Officer
Michelle LaSpalutoVice President of Strategic Planning and Investor Relations
Dr. Michael A. AlrutzSenior Vice President, General Counsel and Corporate Secretary
Dr. Joshua E. AllenChief Technology Officer of Imipridones

Latest SEC Filings

May 20, 20224Statement of changes in beneficial ownership of securities
May 20, 20224Statement of changes in beneficial ownership of securities
May 18, 20228-KCurrent report
May 18, 20224Statement of changes in beneficial ownership of securities
May 17, 20224Statement of changes in beneficial ownership of securities
May 16, 202210-QQuarterly report [Sections 13 or 15(d)]
May 16, 20228-KCurrent report
May 4, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 3, 2022EFFECTNotice of Effectiveness
May 2, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
View All SEC Filings